Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Rimonabant: Additional Phase III data

Researchers published in The Lancet a meta-analysis of the 4 double-blind Phase III RIO trials in a total of 4,105 obese patients which showed that patients receiving 20 mg of rimonabant

Read the full 318 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE